


737 F.3d 731
United States Court of Appeals,
Federal Circuit.
GALDERMA LABORATORIES, L.P., Galderma S.A., and Galderma Research and Development, S.N.C., Plaintiffs-Appellees,
v.
TOLMAR, INC., Defendant-Appellant.
No. 2013-1034.
|
Dec. 11, 2013.
|
Rehearing and Rehearing En Banc Denied March 27, 2014.
Synopsis
Background: Patentee brought infringement action against generic drug manufacturer, alleging infringement of its patents for a topical acne medication. The United States District Court for the District of Delaware, Leonard P. Stark, J., 891 F.Supp.2d 588, ruled that the patents were not invalid as obvious, and defendant appealed.
 
The Court of Appeals, Prost, Circuit Judge, held that the patents, which taught use of active ingredient at 0.3% concentration, were invalid as obvious in light of prior art that disclosed preferred range of 0.01%-1% for that ingredient, with same inactive ingredients.
 
Reversed.
 
Newman, Circuit Judge, filed dissenting opinion.
 
